Navigation Links
Cepheid Reports 2013 First Quarter Results
Date:4/18/2013

er unforeseen supply, development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the Company's reliance on distributors in some regions to market, sell and support its products; the occurrence of unforeseen expenditures, acquisitions or other transactions; costs associated with litigation; the impact of competitive products and pricing; the Company's ability to manage geographically-dispersed operations; and underlying market conditions worldwide.  Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K and its other reports filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

FINANCIAL TABLES FOLLOWCEPHEIDCONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF OPERATIONS(in thousands, except per share data)Three Months Ended March 31, 20132012Sales:System and other sales

$
,010$
5,230Reagent and disposable sales

75,92862,062Total sales

91,93877,292Costs and operating expenses:Cost of sales 

42,89235,608Collaboration profit sharing 

2,1101,684Research and development

17,72722,102Sales and marketing

19,12614,512General and administrative

9,76311,051Total costs and operating expenses 

91,61884,957Income (loss) from operations 

320(7,665)Other income, net

374238Income (loss) before income taxes

694(7,427)Benefit from (provision for) income taxes

(381)1,901Net income (loss)

$
313$
(5,526)Basic net income (
'/>"/>

SOURCE Cepheid
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
2. Cepheid Announces Board of Directors Changes
3. Cepheid Reports 2012 Second Quarter Results
4. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
5. Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae
6. Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
7. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
8. Cepheid to Webcast Upcoming Financial Presentations
9. Cepheid Reports Fourth Quarter and Full Year 2011 Results
10. Cepheid Welcomes Senior Vice President of Human Resources
11. Global Nano-Materials Market 2002-2016: Nano-Materials Industry, Production Volumes, Revenues and End User Market Demand - MarketResearchReports.Biz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Frederick, MD (PRWEB) November 21, 2014 ... sample management solutions provider, has released Limfinity® version ... more installation projects of Limfinity® than ever in ... majority configuration and minority framework enhancement. Limfinity® version ... goes far above and beyond bug fixes! , ...
(Date:11/22/2014)... LAVAL, Quebec , November 21, 2014 ... Martensen wechselt als Chief Commercial Officer zu KLOX ... zum SVP der Unternehmensentwicklung und Chief Financial Officer bestellt ... in Europa mit der Vermarktung seines jüngst zugelassenen Behandlungssystems ... Technologies Inc. ("KLOX" bzw. das "Unternehmen") ist sehr erfreut, ...
(Date:11/21/2014)... 20, 2014 Author Matthew J. Pallamary’s ... the Other Side” published as a tribute to ... the “Fiction: Short Story” category of the 2014 ... and CEO of USA Book News, said this year’s ... publishers, including Simon & Schuster, Penguin, John Wiley & ...
(Date:11/21/2014)... 21, 2014 Why did Stephen Hawking ... Einstein so instantly recognizable? Why have they become icons ... and author Hilton Ratcliffe seeks out the answers to ... all to do with science. In " Stephen Hawking ... November 21, 2014), Ratcliffe puts it plainly: , ...
Breaking Biology Technology:RURO Announces Limfinity® version 5.1.4 2KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4
... Nov. 27 Nastech,Pharmaceutical Company Inc. (Nasdaq: NSTK ... Capital Markets Focus on Healthcare Conference on,Wednesday, December 5, ... Hotel in New York City., To access the ... to,Nastech,s website at http://www.nastech.com approximately 15 minutes ...
... FDA 510(k) (Pre-Market Notification), Pathway for AppyScore(TM), the First Blood-based Screening ... ... Colo., Nov. 27 AspenBio Pharma,Inc. (Nasdaq: APPY ) an ... for animals and humans, has,received an official response from the Food ...
... - Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) ("Oncolytics") ... 7,300,650 entitled "Reovirus for the Treatment of Neoplasia.",The ... treat cancers that,have inactivated PKR, whether the PKR ... factors. PKR is a host cellular protein responsible ...
Cached Biology Technology:AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 2AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 3AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 4Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent 2
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... CLEVELAND/ORLANDO University Hospitals Case Medical Center researchers ... a second chancejust not as they originally thought. ... harnessed from bone marrow that were believed to have ... if injected into the heart within two weeks of ...
... step closer to understanding what drives tumor metastasis, as ... can slow their own growth. In a recent ... the American Association for Cancer Research, Ral A. Ruggiero, ... medicine at the National Academy of Medicine in Buenos ...
... Findings from preclinical studies in a skin ... alone, or first-generation BRAF inhibitors used in combination ... have the potential to prevent drug-induced skin lesions ... The studies, presented at the AACR-NCI-EORTC International ...
Cached Biology News:Post heart attack recovery may not be aided by stem cell injections, but trial demonstrates promise 2New approaches may prevent certain side effects in BRAF mutation-positive melanoma 2
Kit Components: Anti-Acetylated Histone H3 Salmon Sperm DNA/Protein A Agarose All necessary buffers. ...
Liquid. 50 μg/ml in PBS, pH 7.4. PROTECT FROM LIGHT. A convenient form of propidium iodide useful for flow cytometry studies. RTECS SF7949600, CAS 25535-16-4, M.W. 668.4. ...
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... ChipWriter Pro systems are high-precision microarrayers ... other biological samples. VersArray ChipWriter Pro ... spot density, and reproducibility to deliver ... of substrates. Their modular component design ...
Biology Products: